News

The newly released manuscript describes key safety and immunogenicity data from the U.S. Phase 1 trial for the BNT162b2 vaccine candidate, which at 30μg recorded 7 days after

The approval allows Kesimpta to be used as an injection for subcutaneous use to treat RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in

This ongoing registrational study is investigating motixafortide (BL-8040) for the mobilization of hematopoietic stem cells (HSCs) for autologous transplantation in patients with multiple myeloma. If the primary endpoint

The acquisition of Momenta Pharmaceuticals is expected to help the Janssen Pharmaceutical Companies of Johnson & Johnson to grow its position further in immune-mediated diseases and bring in

With a grant totaling € 77.7 million, CARE is funded by cash contributions from the European Union (EU) and cash and in-kind contributions from eleven European Federation of

If approved, Imfinzi could be administered intravenously every four weeks at a fixed dose of 1500mg in unresectable Stage III NSCLC after chemoradiation therapy and previously treated advanced bladder cancer,

TYVYT, which was co-developed by Innovent and Lilly in China, is an anti-PD-1 monoclonal antibody immuno-oncology medicine. The duo began selling the drug in the country since 2019

Situated in Frederick of Colorado, the advanced facility is engaged in the development and manufacturing of oligos that are short DNA and RNA molecules used for the creation

The trial was a randomized, double-blind, placebo-controlled, multi-center, dose escalation study assessing the safety and efficacy of F351 for Hepatic Fibrosis in Chronic Viral Hepatitis B patients in